• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Recent Advances in the Study of N-Butyl-4-nitrobenzenesulfonamide (CAS: 66473-14-1)

N-Butyl-4-nitrobenzenesulfonamide (CAS: 66473-14-1) is a sulfonamide derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by the presence of a nitro group and a butyl chain attached to a benzenesulfonamide core, has been the subject of various studies aimed at exploring its biological activity, synthetic pathways, and pharmacological properties. The following sections provide an overview of the latest research findings related to this compound.

Recent studies have focused on the synthesis and optimization of N-Butyl-4-nitrobenzenesulfonamide. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel, high-yield synthetic route that utilizes palladium-catalyzed cross-coupling reactions to improve the efficiency of production. This method not only reduces the number of synthetic steps but also enhances the purity of the final product, making it more suitable for pharmaceutical applications. The study also highlighted the compound's stability under various pH conditions, which is a critical factor for its potential use in drug formulations.

In terms of biological activity, N-Butyl-4-nitrobenzenesulfonamide has shown promising results as an inhibitor of carbonic anhydrase enzymes. A 2022 study published in Bioorganic & Medicinal Chemistry Letters demonstrated that this compound exhibits selective inhibition of carbonic anhydrase IX (CA IX), an enzyme overexpressed in many solid tumors. The researchers used X-ray crystallography to elucidate the binding mode of the compound within the active site of CA IX, providing valuable insights for the design of more potent and selective inhibitors. These findings suggest that N-Butyl-4-nitrobenzenesulfonamide could serve as a lead compound for the development of anticancer therapies.

Another area of interest is the compound's potential antimicrobial properties. A 2023 study in the European Journal of Pharmaceutical Sciences investigated the efficacy of N-Butyl-4-nitrobenzenesulfonamide against a panel of Gram-positive and Gram-negative bacteria. The results indicated moderate activity against Staphylococcus aureus and Escherichia coli, with minimum inhibitory concentrations (MICs) comparable to those of established sulfonamide antibiotics. However, the study also noted that further structural modifications may be necessary to enhance its antimicrobial potency and reduce potential toxicity.

Pharmacokinetic studies of N-Butyl-4-nitrobenzenesulfonamide have also been conducted to evaluate its suitability as a drug candidate. A 2023 preclinical study published in Drug Metabolism and Disposition reported that the compound exhibits favorable oral bioavailability and a relatively long half-life in rodent models. These properties, combined with its low plasma protein binding, suggest that N-Butyl-4-nitrobenzenesulfonamide could be a viable candidate for further development. However, the study also identified the need for additional toxicology assessments to ensure its safety profile.

In conclusion, recent research on N-Butyl-4-nitrobenzenesulfonamide (CAS: 66473-14-1) has highlighted its potential as a versatile scaffold for drug discovery. Its inhibitory activity against carbonic anhydrase IX, moderate antimicrobial properties, and favorable pharmacokinetic profile make it a compound of interest for further investigation. Future studies should focus on optimizing its structure to enhance efficacy and reduce toxicity, as well as exploring its potential in combination therapies. The continued exploration of this compound may yield valuable contributions to the fields of oncology, infectious diseases, and beyond.

• 52374-17-1(Benzenesulfonamide, N-hexyl-3-nitro-)
• 477723-14-1(Benzenesulfonamide, N-cyclobutyl-4-nitro-)
• 23530-47-4(4-Nitro-N-Propyl-Benzenesulfonamide)
• 477723-15-2
• 52374-18-2(Benzenesulfonamide,N-hexyl-4-nitro-)
• 52374-21-7(Benzenesulfonamide, 4-nitro-N-octyl-)
• 89840-75-5(Benzenesulfonamide, 3-nitro-N-octyl-)
• 89840-71-1(3-nitro-N-propylbenzene-1-sulfonamide)
• 89840-80-2(N-ISOBUTYL-4-NITROBENZENESULFONAMIDE)
• 89840-72-2(N-Butyl 3-Nitrobenzenesulfonamide)